Evofem Biosciences Reports 45% Decline in Q2 2026 Net Sales, Faces Financial Challenges

Evofem Biosciences, Inc. reported a significant decline in financial performance for the second quarter of 2026, with net product sales of $2.6 million, a 45% decrease from $4.8 million in the same period of 2025. For the first half of 2026, the company generated $3.5 million in net sales, down 38% from $5.7 million in the prior year. The decrease in sales was attributed to a reduction in PHEXX units sold, following a surge in purchases by wholesalers in December 2025 ahead of a price increase, as well as temporary exclusions from certain state Medicaid programs. The company also reported a net loss of $11.0 million for the quarter, compared to a loss of $1.8 million in the previous year.

Evofem's total operating expenses for the second quarter were $5.1 million, down from $6.1 million in the same quarter of 2025. The reduction was primarily due to lower selling and marketing expenses, which decreased by 21% to $2.1 million, reflecting cost-cutting measures including the termination of a commercial rebate program. Research and development expenses remained relatively stable at $694,000, while general and administrative expenses were nearly unchanged at $1.8 million. The company also reported a significant increase in other expenses, primarily due to a $5.7 million loss related to the change in fair value of financial instruments.

In terms of operational developments, Evofem has focused on expanding its product offerings and market reach. The company acquired global rights to SOLOSEC in July 2024, which is expected to enhance its portfolio in women's health. Evofem has also entered into licensing agreements for both PHEXX and SOLOSEC in the Middle East and North Africa, with Pharma 1 Drug Store, and established a distributorship agreement with Clovis Davis Pharmaceuticals for SOLOSEC in sub-Saharan Africa. These strategic moves aim to bolster the company's presence in international markets.

As of June 30, 2026, Evofem reported a working capital deficit of $82.5 million and an accumulated deficit of $914 million. The company has indicated that its cash resources are insufficient to fund operations for the next 12 months, raising concerns about its ability to continue as a going concern. Management plans to address this by generating revenue from product sales, restructuring payables, and seeking additional funding through various means, including potential partnerships and licensing agreements. The company has acknowledged that failure to secure necessary funding could lead to further operational reductions or even cessation of operations.

Looking ahead, Evofem anticipates continued challenges in achieving profitability, with expectations of ongoing net losses. The company is actively pursuing strategies to enhance its market position and financial stability, including expanding its sales and marketing efforts for PHEXX and SOLOSEC, while also exploring new market opportunities. However, the uncertainties surrounding its financial condition and the need for additional capital raise significant concerns about its future operations.